Deborah A Levine1,2,3, Andrzej T Galecki1,4, Lewis B Morgenstern2,3,5, Darin B Zahuranec2, Kenneth M Langa1,3,6, Mohammed U Kabeto1, Dolorence Okullo1, Brahmajee K Nallamothu1,3,6, Bruno Giordani7, Bailey K Reale1, Morgan Campbell8, Lynda D Lisabeth2,5. 1. Department of Internal Medicine and Cognitive Health Services Research Program (D.A.L., A.T.G., K.M.L., M.U.K., D.O., B.K.N., B.K.R.), University of Michigan, Ann Arbor. 2. Department of Neurology and Stroke Program (D.A.L., L.B.M., D.B.Z., L.D.L.), University of Michigan, Ann Arbor. 3. Institute for Healthcare Policy and Innovation (D.A.L., L.B.M., K.M.L., B.K.N.), University of Michigan, Ann Arbor. 4. Department of Biostatistics (A.T.G.), University of Michigan, Ann Arbor. 5. Department of Epidemiology (L.B.M., L.D.L.), University of Michigan, Ann Arbor. 6. VA Ann Arbor Healthcare System, MI (K.M.L., B.K.N.). 7. Department of Psychiatry and Michigan Alzheimer's Disease Center (B.G.), University of Michigan, Ann Arbor. 8. Neuroscience Institute and Stroke Program Medical Director, Christus Spohn Shoreline, Corpus Christi, TX (M.C.).
Abstract
BACKGROUND AND PURPOSE: Differences in acute ischemic stroke (AIS) treatment by cognitive status are unclear, but some studies have found patients with preexisting dementia get less treatment. We compared AIS care by preexisting cognitive status. METHODS: Cross-sectional analysis of prospectively obtained data on 836 adults ≥45 with AIS from the population-based Brain Attack Surveillance in Corpus Christi project from 2008 to 2013. We compared receipt of a composite quality measure representing the percentage of 7 treatments/procedures received (ordinal scale; values, <0.75, 0.75-0.99, and 1.0), a binary defect-free quality score, and individual treatments after AIS between patients with preexisting dementia (Informant Questionnaire on Cognitive Decline in the Elderly score ≥3.44), mild cognitive impairment (MCI, score 3.1-3.43), and normal cognition (score ≤3). RESULTS: Among patients with AIS, 42% had normal cognition (47% women; median age [interquartile range], 65 [56-76]), 32% had MCI (54% women; median age, 70 [60-78]), 26% had dementia (56% women; median age, 78 [64-85]). After AIS, 44% of patients with preexisting dementia and 55% of patients with preexisting MCI or normal cognition received defect-free care. Compared with cognitively normal patients, patients with preexisting MCI had similar cumulative odds (unadjusted cumulative odds ratio =0.99, P=0.92), and patients with preexisting dementia had 36% lower cumulative odds of receiving the composite quality measure (unadjusted cumulative odds ratio [OR]=0.64, P=0.005). However, the dementia-quality association became nonsignificant after adjusting for patient factors, namely sex, comorbidity, and body mass index (adjusted cumulative OR [acOR]=0.79, P=0.19). Independent of patient factors, preexisting MCI was negatively associated with receipt of IV tPA (intravenous tissue-type plasminogen activator; acOR=0.36, P=0.04), rehabilitation assessment (acOR=0.28, P=0.016), and echocardiogram (acOR=0.48, P<0.001). Preexisting dementia was negatively associated with receipt of antithrombotic by day 2 (acOR=0.39, P=0.04) and echocardiogram (acOR=0.42, P<0.001). CONCLUSIONS: Patients with preexisting MCI and dementia, compared with cognitively normal patients, may receive less frequently some treatments and procedures, but not the composite quality measure, after AIS.
BACKGROUND AND PURPOSE: Differences in acute ischemic stroke (AIS) treatment by cognitive status are unclear, but some studies have found patients with preexisting dementia get less treatment. We compared AIS care by preexisting cognitive status. METHODS: Cross-sectional analysis of prospectively obtained data on 836 adults ≥45 with AIS from the population-based Brain Attack Surveillance in Corpus Christi project from 2008 to 2013. We compared receipt of a composite quality measure representing the percentage of 7 treatments/procedures received (ordinal scale; values, <0.75, 0.75-0.99, and 1.0), a binary defect-free quality score, and individual treatments after AIS between patients with preexisting dementia (Informant Questionnaire on Cognitive Decline in the Elderly score ≥3.44), mild cognitive impairment (MCI, score 3.1-3.43), and normal cognition (score ≤3). RESULTS: Among patients with AIS, 42% had normal cognition (47% women; median age [interquartile range], 65 [56-76]), 32% had MCI (54% women; median age, 70 [60-78]), 26% had dementia (56% women; median age, 78 [64-85]). After AIS, 44% of patients with preexisting dementia and 55% of patients with preexisting MCI or normal cognition received defect-free care. Compared with cognitively normal patients, patients with preexisting MCI had similar cumulative odds (unadjusted cumulative odds ratio =0.99, P=0.92), and patients with preexisting dementia had 36% lower cumulative odds of receiving the composite quality measure (unadjusted cumulative odds ratio [OR]=0.64, P=0.005). However, the dementia-quality association became nonsignificant after adjusting for patient factors, namely sex, comorbidity, and body mass index (adjusted cumulative OR [acOR]=0.79, P=0.19). Independent of patient factors, preexisting MCI was negatively associated with receipt of IV tPA (intravenous tissue-type plasminogen activator; acOR=0.36, P=0.04), rehabilitation assessment (acOR=0.28, P=0.016), and echocardiogram (acOR=0.48, P<0.001). Preexisting dementia was negatively associated with receipt of antithrombotic by day 2 (acOR=0.39, P=0.04) and echocardiogram (acOR=0.42, P<0.001). CONCLUSIONS: Patients with preexisting MCI and dementia, compared with cognitively normal patients, may receive less frequently some treatments and procedures, but not the composite quality measure, after AIS.
Entities:
Keywords:
body mass index; dementia; ischemic stroke; population; quality of health care
Authors: Melinda A Smith; Jan M H Risser; Lemuel A Moyé; Nelda Garcia; Olubumi Akiwumi; Ken Uchino; Lewis B Morgenstern Journal: Ethn Dis Date: 2004 Impact factor: 1.847
Authors: Mollie McDermott; Lynda D Lisabeth; Jonggyu Baek; Eric E Adelman; Nelda M Garcia; Erin Case; Morgan S Campbell; Lewis B Morgenstern; Darin B Zahuranec Journal: J Stroke Cerebrovasc Dis Date: 2017-05-04 Impact factor: 2.136
Authors: Lesli E Skolarus; Brisa N Sanchez; Deborah A Levine; Jonggyu Baek; Kevin A Kerber; Lewis B Morgenstern; Melinda A Smith; Lynda D Lisabeth Journal: Circ Cardiovasc Qual Outcomes Date: 2013-12-10
Authors: Brenda L Plassman; Kenneth M Langa; Gwenith G Fisher; Steven G Heeringa; David R Weir; Mary Beth Ofstedal; James R Burke; Michael D Hurd; Guy G Potter; Willard L Rodgers; David C Steffens; John J McArdle; Robert J Willis; Robert B Wallace Journal: Ann Intern Med Date: 2008-03-18 Impact factor: 25.391
Authors: Helena Bárrios; Sofia Narciso; Manuela Guerreiro; João Maroco; Rebecca Logsdon; Alexandre de Mendonça Journal: Aging Ment Health Date: 2012-12-07 Impact factor: 3.658
Authors: Lewis B Morgenstern; Melinda A Smith; Brisa N Sánchez; Devin L Brown; Darin B Zahuranec; Nelda Garcia; Kevin A Kerber; Lesli E Skolarus; William J Meurer; James F Burke; Eric E Adelman; Jonggyu Baek; Lynda D Lisabeth Journal: Ann Neurol Date: 2013-08-13 Impact factor: 10.422
Authors: Blossom C M Stephan; Kathryn Richardson; George M Savva; Fiona E Matthews; Carol Brayne; Vladimir Hachinski Journal: J Am Geriatr Soc Date: 2017-04-03 Impact factor: 5.562
Authors: Emilie M Blair; Darin B Zahuranec; Jane Forman; Bailey K Reale; Kenneth M Langa; Bruno Giordani; Angela Fagerlin; Colleen Kollman; Rachael T Whitney; Deborah A Levine Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.472